Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Akorn Inc (NQ: AKRX )

0.0900 USD UNCHANGED
Last Price Updated: 7:59 PM EDT, May 29, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Akorn Inc

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Akorn to Use Voluntary Chapter 11 Process to Position Business for Long-Term Success
Continues Operations as Usual, Delivering Safe and Effective Products to Customers and Patients 
From PR Newswire
Akorn Provides First Quarter 2020 Results
From GlobeNewswire News Releases
Thinking about buying stock in Myomo, Microvision, Akorn Inc, Callon Petroleum, or Recon Technology?
InvestorsObserver issues critical PriceWatch Alerts for MYO, MVIS, AKRX, CPE, and RCON. 
From PR Newswire
Enphase Energy and Paylocity Set to Join S&P MidCap 400; Core Laboratories and Meredith to Join S&P SmallCap 600
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the open of trading on Friday, May 1: 
From PR Newswire
Akorn Provides Update on Sale Process
Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced that it no longer has any bids in the Sale Process that are sufficient to pay all obligations under its term loan... 
From PR Newswire
Akorn Provides Fourth Quarter and Full Year 2019 Results
From GlobeNewswire News Releases
Akorn Announces New Extension of Standstill with Lenders and Agrees to Pursue a Sale of its Business
Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced it has reached an agreement with certain of its lenders to extend the standstill period. The agreement defines a... 
From PR Newswire
Akorn Continues Negotiations with Lenders
Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today confirmed that negotiations with certain of its lenders are ongoing following the expiration of its standstill agreement on... 
From PR Newswire
Akorn Announces Extension of Standstill Agreement
From GlobeNewswire News Releases
Akorn to Present at the Credit Suisse Healthcare Conference
From GlobeNewswire News Releases
Akorn Provides Preliminary Third Quarter 2019 Results
Updates net loss and affirms net revenue and adjusted EBITDA guidance 
From GlobeNewswire News Releases
Akorn Receives FDA Approval for Betamethasone Dipropionate Lotion USP (Augmented), 0.05%
From GlobeNewswire News Releases
Akorn to Report Third Quarter 2019 Financial Results and Host Conference Call
From GlobeNewswire News Releases
Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.15%
From GlobeNewswire News Releases
Akorn to Report Second Quarter 2019 Financial Results and Host Conference Call
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release before market open on Thursday, August 1, 2019 outlining its... 
From GlobeNewswire News Releases
Akorn Announces Launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it has launched its first-to-market generic of Loteprednol Etabonate Ophthalmic Suspension, 0.5%. 
From GlobeNewswire News Releases
Akorn Receives FDA Warning Letter
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, announced that it received a warning letter from the U.S. Food and Drug Administration (FDA) related to the inspection of... 
From GlobeNewswire News Releases
Akorn to Present at the Jefferies 2019 Global Healthcare Conference
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019... 
From GlobeNewswire News Releases
Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug... 
From GlobeNewswire News Releases
NASDAQ:AKRX Long Term Investor Alert: Investigation of Potential Wrongdoing at Akorn, Inc.
San Diego, CA -- (SBWIRE) -- 05/20/2019 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Akorn, Inc.. 
From SBWire - Latest Press Releases
Akorn to Present at the RBC Capital Markets Healthcare Conference
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the 2019 RBC Capital Markets Healthcare Conference on Wednesday, May 22,... 
From GlobeNewswire News Releases
Akorn Provides Preliminary First Quarter 2019 Results and Full Year Guidance
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced its preliminary financial results for the first quarter of 2019. 
From GlobeNewswire News Releases
Report: Developing Opportunities within Hawaiian Electric Industries, Landstar System, Ladenburg Thalmann Financial Services, and Akorn — Future Expectations, Projections Moving into 2019
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Hawaiian Electric... 
From GlobeNewswire News Releases
Glancy Prongay & Murray LLP Files a Securities Class Action Notifying Investors of Expanded Class Period (AKRX)
Glancy Prongay & Murray LLP Files a Securities Class Action Notifying Investors of Expanded Class Period (AKRX) 
From Business Wire News Releases
FINAL DEADLINE ALERT - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the... 
From GlobeNewswire News Releases
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akorn, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the April 22, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Akorn, Inc. (“Akorn”... 
From GlobeNewswire News Releases
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Akorn, Inc. (“Akorn” or “the Company”) (NASDAQ: AKRX) for violations of... 
From GlobeNewswire News Releases
Block & Leviton LLP Reminds Shareholders of Important Deadlines: AKRX, SYNH, INGN, BPI
Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, reminds investors of the important deadlines listed below. If you have purchased or otherwise... 
From GlobeNewswire News Releases
Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5%
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug... 
From GlobeNewswire News Releases
Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.